A Phase III, 52-week, Open-label Study to Evaluate Long-term Safety of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Patients With Asthma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Salbutamol
- Indications Asthma
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 26 Jul 2018 Planned End Date changed from 1 Aug 2019 to 24 Jun 2019.
- 26 Jul 2018 Planned primary completion date changed from 1 Aug 2019 to 24 Jun 2019.